These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11268498)

  • 1. Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels.
    Befon S; Mystakidou K; Lyra M; Tubanakis N; Vlahos L
    Anticancer Res; 2000; 20(5C):4039-46. PubMed ID: 11268498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
    Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
    Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
    Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
    Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous subcutaneous administration of high-dose salmon calcitonin in bone metastasis: pain control and beta-endorphin plasma levels.
    Mystakidou K; Befon S; Hondros K; Kouskouni E; Vlahos L
    J Pain Symptom Manage; 1999 Nov; 18(5):323-30. PubMed ID: 10584455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
    Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide in advanced prostatic cancer relapsing under hormonal treatment.
    Verhelst J; De Longueville M; Ongena P; Denis L; Mahler C
    Acta Urol Belg; 1994 Apr; 62(1):83-8. PubMed ID: 7515212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between pain severity and serum beta-endorphin levels in postoperative patients.
    Leonard TM; Klem SA; Asher MA; Rapoff MA; Leff RD
    Pharmacotherapy; 1993; 13(4):378-81. PubMed ID: 8361864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Beta-endorphin levels before and after relief of cancer pain.
    El-Sheikh N; Boswell MV
    Pain Physician; 2004 Jan; 7(1):67-70. PubMed ID: 16868614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in psychosocial outcomes in chronic pain patients receiving intrathecal morphine infusions.
    Duse G; Davià G; White PF
    Anesth Analg; 2009 Dec; 109(6):1981-6. PubMed ID: 19923529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis.
    Thomopoulos KC; Pagoni NA; Vagenas KA; Margaritis VG; Theocharis GI; Nikolopoulou VN
    Gastrointest Endosc; 2006 Nov; 64(5):726-31. PubMed ID: 17055865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The analgesic effect of pamidronate is not caused by the elevation of beta endorphin level in Paget's disease--a controlled pilot study.
    Bender T; Donáth J; Barna I; Gergely P; Poór G
    Neuro Endocrinol Lett; 2006 Aug; 27(4):513-5. PubMed ID: 16891991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.
    Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA
    Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide inhibits pancreatic exocrine secretion and prevents pancreatoenterostomy leakage.
    Nakatsuka A; Yamaguchi K; Chijiiwa K; Tanaka M
    Int Surg; 2000; 85(2):124-9. PubMed ID: 11071328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial.
    Abid S; Jafri W; Hamid S; Salih M; Azam Z; Mumtaz K; Shah HA; Abbas Z
    Am J Gastroenterol; 2009 Mar; 104(3):617-23. PubMed ID: 19223890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping.
    Arts J; Caenepeel P; Bisschops R; Dewulf D; Holvoet L; Piessevaux H; Bourgeois S; Sifrim D; Janssens J; Tack J
    Clin Gastroenterol Hepatol; 2009 Apr; 7(4):432-7. PubMed ID: 19264574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
    Penning C; Vecht J; Masclee AA
    Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Octreotide in the treatment of advanced pancreatic tumor. Preliminary study].
    Cirillo F; Bottini A; Brunelli A; Zuffada S; Bassi M; Filippini L; Alquati P
    Minerva Chir; 1998 Dec; 53(12):979-85. PubMed ID: 10210927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.